No DTC Ads For Controversial Female Sex Pill
This article was originally published in Scrip
Executive Summary
The controversial libido-boosting pill Addyi (flibanserin) was launched in the US over this past weekend with little fanfare – and no direct-to-consumer (DTC) ads, or at least, not yet.